Fugro NL Services B.V.

NLC Health Ventures operates as a systematic venture builder and early-stage investment fund focused on healthcare technology commercialization. Founded in 2014 and headquartered in the Netherlands with operations across Europe and the United States, the organization employs a structured process to identify promising healthcare innovations from universities, academic hospitals, and corporations, then transforms selected technologies into market-ready companies. The technical approach centers on bridging the gap between academic research and clinical deployment, with a team of over 40 specialists applying what they describe as entrepreneurship at scale to accelerate time-to-market for medical innovations. The organization's operational model produces approximately 25 new ventures annually and maintains a portfolio exceeding 100 active ventures across its geographic footprint. This volume reflects a repeatable system for early-stage venture creation rather than ad-hoc project development. NLC provides ventures with shared resources, technical expertise, and commercialization support through the NLC Health Impact Fund, which finances the transition from laboratory validation to patient-facing products. The venture builder operates at the intersection of medical device development, digital health systems, and healthcare service delivery, working with source institutions that have completed foundational research but require specialized capabilities to navigate regulatory pathways, clinical validation requirements, and market entry strategies. For engineers, NLC's portfolio companies represent opportunities to work on early-stage healthcare technologies where core technical challenges remain unsolved and system architectures are still being defined. The ventures span medical devices, diagnostic platforms, therapeutic systems, and healthcare IT infrastructure, with technical work occurring at partner institutions and spin-out companies rather than at NLC's central offices. Founded by Bert-Arjan Millenaar, the organization positions itself as Europe's leading early-stage healthtech investor, though specific deployment metrics and clinical outcomes for portfolio companies are not publicly detailed in available materials.

At Coesia, innovation isn't just a buzzword - it's the foundation of how we work and grow together. Our global team of 8,000+ professionals across 34 countries collaborates across specialized companies to deliver cutting-edge industrial and packaging solutions. We believe that diversity and integration are the driving forces behind our ability to innovate, which is why we've built a culture where knowledge sharing and continuous learning are central to everything we do. Our people are at the heart of our organization. We invest deeply in professional growth through targeted development programs like our Young Professional Program, which brings together recent graduates from around the world for intensive training and collaboration. Our commitment to excellence extends beyond technology to the way we work - empowering employees to reach their full potential through coaching, leadership development, and a strong focus on continuous learning. Sustainability guides our innovation, with dedicated labs and initiatives focused on creating eco-friendly packaging solutions that shape a more responsible future for our industry.

Terumo Blood and Cell Technologies is a global leader in medical technology, specializing in blood component collection, therapeutic apheresis, and cellular therapy technologies that impact patients' lives every second of every day. With more than 8,000 global associates and operations spanning 130+ countries, the company's innovative solutions enable healthcare providers to deliver life-saving treatments worldwide. Their products process blood components safely, treat serious medical conditions through therapeutic plasma exchange, and advance cellular therapy manufacturing - all while maintaining a patient-centered approach that drives measurable results across their core business areas. Headquartered in Lakewood, Colorado, Terumo BCT operates as part of Terumo Corporation (TSE:4543), a Tokyo-based global healthcare leader founded in 1921. The company's commitment extends beyond technology to include partnerships with organizations like The Leukemia & Lymphoma Society, comprehensive blood safety initiatives, and the 'From the Heart' global program designed to educate and empower communities. Through platforms like Quantum Flex Cell Expansion System for CAR-T therapies and Spectra Optia Apheresis System for treating conditions like sickle cell disease, Terumo BCT continues to expand access to critical treatments and shape the future of blood and cell-based therapies.

Getinge is a global medical technology company founded in 1904, dedicated to making life-saving technology accessible to more people. With a passion for life that drives everything they do, Getinge provides hospitals and life science institutions with products and solutions that improve clinical results and optimize workflows across intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, and life sciences. Headquartered in Gothenburg, Sweden, Getinge has grown from a small rural town into a global medical technology leader with approximately 12,000 employees operating in 40 countries and sales in more than 135 countries. The company achieved 31.8 billion SEK in net sales in 2023 and has been listed on the Nasdaq Stockholm Large Cap since 1993. From ventilators trusted by healthcare providers worldwide to sterilization systems and surgical workflow solutions, Getinge stands behind the moments that matter - for every life saved and every breakthrough made.

Accenture B.V. operates as part of Accenture, a global professional services company led by CEO Julie Sweet and headquartered in the United States. The organization serves businesses, governments, and organizations worldwide, delivering services across four primary capability areas: strategy and consulting, interactive, technology, and operations. Accenture positions itself as helping clients build digital core systems, optimize operations, and accelerate revenue growth through what it describes as technology-enabled, human-centered approaches. The company's technology capability area focuses on implementing digital transformation initiatives and building digital core infrastructure for clients. Its operations practice works on optimizing existing systems and processes. Accenture provides these services across more than 40 industries, combining domain expertise with technical implementation capabilities. The organization emphasizes stakeholder value creation, measuring outcomes across clients, employees, shareholders, partners, and communities rather than focusing solely on client deliverables. For engineers, Accenture's scale offers exposure to implementations across diverse sectors and geographies. The company's technical work spans digital transformation projects, operations optimization systems, and technology platform development. Projects typically involve integrating multiple technical domains to address enterprise-scale challenges, with implementations occurring in production environments serving large organizations globally.

KRUSH LABS is Key Research in Unmanned Systems and Hardware, a global multicultural privately-owned new-generation research center founded in 2025 in Eindhoven, Netherlands. The company exists to bridge the critical gap between emerging technology and real-world application, developing cutting-edge wireless communication systems for mission-critical applications where reliability and performance are non-negotiable. In industries ranging from aerospace and autonomous mobility to precision agriculture, every second of connectivity and every decision made by autonomous systems matters - KRUSH Labs delivers the foundational technologies that make these systems possible. The company pursues high-quality, practice-oriented research that transforms scientific discovery into deployable solutions across communications, navigation, embedded systems, and cybersecurity. By combining advanced software-defined radio technology with custom hardware, next-generation GNSS with AI-enhanced visual-inertial odometry, and robust encryption with intelligent control systems, KRUSH Labs empowers clients to operate with confidence in complex, GNSS-denied, and interference-heavy environments. With a team averaging 15+ years of research experience and representing 11+ countries, KRUSH Labs fuses global expertise with local insight to shape the technologies that will define the future of unmanned systems and hardware innovation.